155 related articles for article (PubMed ID: 29995828)
1. Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis.
Liu X; Li X; Zhang C; Sun M; Sun Z; Xu Y; Tian X
Medicine (Baltimore); 2018 Jul; 97(28):e11547. PubMed ID: 29995828
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials.
Li X; Hou Y; Su Y; Liu H; Zhang B; Fang S
Medicine (Baltimore); 2020 Apr; 99(14):e19573. PubMed ID: 32243377
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
Li X; Zhu L; Zhou C; Liu J; Du H; Wang C; Fang S
PLoS One; 2018; 13(3):e0194501. PubMed ID: 29558528
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.
Asakura S; Tajima O; Koyama T
Int J Neuropsychopharmacol; 2007 Apr; 10(2):263-74. PubMed ID: 16573847
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.
Westenberg HG; Stein DJ; Yang H; Li D; Barbato LM
J Clin Psychopharmacol; 2004 Feb; 24(1):49-55. PubMed ID: 14709947
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.
Asakura S; Hayano T; Hagino A; Koyama T
Curr Med Res Opin; 2016; 32(4):749-57. PubMed ID: 26808688
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
Williams T; McCaul M; Schwarzer G; Cipriani A; Stein DJ; Ipser J
Acta Neuropsychiatr; 2020 Aug; 32(4):169-176. PubMed ID: 32039743
[TBL] [Abstract][Full Text] [Related]
9. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
Davidson J; Yaryura-Tobias J; DuPont R; Stallings L; Barbato LM; van der Hoop RG; Li D
J Clin Psychopharmacol; 2004 Apr; 24(2):118-25. PubMed ID: 15206657
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
Baldwin DS; Asakura S; Koyama T; Hayano T; Hagino A; Reines E; Larsen K
Eur Neuropsychopharmacol; 2016 Jun; 26(6):1062-9. PubMed ID: 26971233
[TBL] [Abstract][Full Text] [Related]
11. Baseline Severity as a Moderator of the Waiting List-Controlled Association of Cognitive Behavioral Therapy With Symptom Change in Social Anxiety Disorder: A Systematic Review and Individual Patient Data Meta-analysis.
Scholten W; Seldenrijk A; Hoogendoorn A; Bosman R; Muntingh A; Karyotaki E; Andersson G; Berger T; Carlbring P; Furmark T; Bouchard S; Goldin P; Kampmann I; Morina N; Kocovski N; Leibing E; Leichsenring F; Stolz T; van Balkom A; Batelaan N
JAMA Psychiatry; 2023 Aug; 80(8):822-831. PubMed ID: 37256597
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.
Li X; Zhu L; Su Y; Fang S
PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.
Zhou Q; Zhao G; Pan Y; Zhang Y; Ni Y
PLoS One; 2024; 19(5):e0300512. PubMed ID: 38753761
[TBL] [Abstract][Full Text] [Related]
15. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials.
Wang ZY; Shi SY; Li SJ; Chen F; Chen H; Lin HZ; Lin JM
Pain Med; 2015 Jul; 16(7):1373-85. PubMed ID: 26176791
[TBL] [Abstract][Full Text] [Related]
18. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes.
Qin B; Huang G; Yang Q; Zhao M; Chen H; Gao W; Yang M
BMJ Open; 2019 Nov; 9(11):e033161. PubMed ID: 31784448
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
Cheer SM; Figgitt DP
Paediatr Drugs; 2001; 3(10):763-81. PubMed ID: 11706925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
